A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC

Sponsor
AstraZeneca
Study ID
NCT07760519
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IMFINZI — OTHER
    IMFINZI

Study Details

This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.

Key Dates

First listed
Aug 12, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Apr 30, 2030
Completion
Apr 30, 2030

Study Design

Enrollment
78 participants (estimated)

Primary Outcome Measure

Frequency and proportion of patients with Grade 3/4 possibly related adverse events (PRAEs)* [ Time Frame: 21 months ]

Central Contacts

Related Studies